指南与共识胸部CT

胸部CT对接受分子靶向药物和免疫检查点抑制剂患者药物相关性肺炎的诊断与临床管理:Fleischner学会立场文件

Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner Society.
指南 / 共识 · Chest · 2021-01-12

Fleischner学会立场文件阐述分子靶向药物和免疫检查点抑制剂相关药物性肺炎(DRP)的诊断与临床管理,强调通过排除其他已知病因进行诊断,采用影像模式法评估肺部异常分布,CT表现包括弥漫性肺泡损伤、单纯性肺嗜酸粒细胞增多症、机化性肺炎、过敏性肺炎和非特异性间质性肺炎,治疗包括停药、免疫抑制治疗及支持措施。

要点

  • DRP诊断通常通过排除其他潜在已知病因实现,需结合用药史与影像模式。
  • CT模式反映急性、亚急性及慢性间质性病变,单一药物可对应多种影像模式。
  • 治疗包括停药、免疫抑制治疗或两者联用,并给予支持措施如补氧和重症监护。

关键影像表现/征象

  • CT模式反映急性(弥漫性肺泡损伤)间质性肺炎和一过性(单纯性肺嗜酸粒细胞增多症)肺部异常。
  • CT模式反映亚急性间质性病变(机化性肺炎和过敏性肺炎)。
  • CT模式反映慢性间质性病变(非特异性间质性肺炎)。
  • 单一药物可伴随多种影像模式。
  • 影像特征应结合肺实质异常的分布进行评估(影像模式法)。

诊断标准与关键数值

  • 诊断DRP通常通过排除其他潜在已知病因实现。
  • 影像评估采用影像模式法,依据肺实质异常的分布。

临床应用与阅片要点

  • 对使用分子靶向药物或免疫检查点抑制剂的患者,阅片时应结合用药史并排除其他已知病因。
  • 报告时应描述肺实质异常的分布,并按影像模式法归类为急性、亚急性或慢性间质性病变。
  • 需注意单一药物可对应多种影像模式。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Use of molecular targeting agents and immune checkpoint inhibitors (ICIs) has increased the frequency and broadened the spectrum of lung toxicity, particularly in patients with cancer. The diagnosis of drug-related pneumonitis (DRP) is usually achieved by excluding other potential known causes. Awareness of the incidence and risk factors for DRP is becoming increasingly important. The severity of symptoms associated with DRP may range from mild or none to life-threatening with rapid progression to death. Imaging features of DRP should be assessed in consideration of the distribution of lung parenchymal abnormalities (radiologic pattern approach). The CT patterns reflect acute (diffuse alveolar damage) interstitial pneumonia and transient (simple pulmonary eosinophilia) lung abnormality, subacute interstitial disease (organizing pneumonia and hypersensitivity pneumonitis), and chronic interstitial disease (nonspecific interstitial pneumonia). A single drug can be associated with multiple radiologic patterns. Treatment of a patient suspected of having DRP generally consists of drug discontinuation, immunosuppressive therapy, or both, along with supportive measures eventually including supplemental oxygen and intensive care. In this position paper, the authors provide diagnostic criteria and management recommendations for DRP that should be of interest to radiologists, clinicians, clinical trialists, and trial sponsors, among others.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Johkoh T, Lee KS, Nishino M, et al. Chest CT Diagnosis and Clinical Management of Drug-Related Pneumonitis in Patients Receiving Molecular Targeting Agents and Immune Checkpoint Inhibitors: A Position Paper From the Fleischner Society. Chest. 2021. PMID: 33450293. doi:10.1016/j.chest.2020.11.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。